Nordicus Partners Corporation is a Denmark-based financial consulting company, specializing in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management’s combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. Nordicus’ 95% owned subsidiary, Orocidin A/S, is a clinical-stage biopharmaceutical company which is advancing the next generation of periodontitis therapies. Nordicus’ core competencies lie in assisting Danish as well as other Nordic and international companies in different areas of corporate finance activities, such as: business valuations, growth strategies, attracting capital for businesses and company acquisitions and sales. For more information about Nordicus, please visit: www.nordicuspartners.com
Company profile
Ticker
NORD
Exchange
Website
CEO
Michael F. Adams
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AdvanSource Biomaterials Corp, CARDIOTECH INTERNATIONAL INC, EKIMAS Corp
SEC CIK
Corporate docs
IRS number
43186647
NORD stock data
Latest filings (excl ownership)
8-K
Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of Directors
4 Jun 24
PRE 14C
Preliminary information
28 May 24
8-K
Nordicus Partners Corporation Acquires 95% Stake in Orocidin A/S
16 May 24
10-Q
2024 Q3
Quarterly report
6 Feb 24
EFFECT
Notice of effectiveness
15 Dec 23
CORRESP
Correspondence with SEC
11 Dec 23
S-1/A
IPO registration (amended)
6 Dec 23
S-1/A
IPO registration (amended)
27 Nov 23
CORRESP
Correspondence with SEC
27 Nov 23
UPLOAD
Letter from SEC
27 Nov 23
Latest ownership filings
3
Therapeutics ApS Alteral
5 Jun 24
SC 13D
Alteral Therapeutics ApS
5 Jun 24
SC 13D
JE Pitzner Holding ApS
5 Jun 24
4
Change in insider ownership
4 Jun 24
SC 13D/A
GK Partners ApS
4 Jun 24
SC 13D/A
GK Partners ApS
26 Mar 24
4
Change in insider ownership
26 Mar 24
SC 13D/A
Rouf Henrik
26 Mar 24
4
Henrik Rouf
26 Mar 24
SC 13D/A
GK Partners ApS
18 Sep 23
Financial summary
Quarter (USD) | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 38.79 k | 38.79 k | 38.79 k | 38.79 k | 38.79 k | 38.79 k |
Cash burn (monthly) | (no burn) | (no burn) | 25.00 k | 230.43 k | 16.96 k | 31.64 k |
Cash used (since last report) | n/a | n/a | 141.00 k | 1.30 mm | 95.64 k | 178.46 k |
Cash remaining | n/a | n/a | -102.21 k | -1.26 mm | -56.86 k | -139.67 k |
Runway (months of cash) | n/a | n/a | -4.1 | -5.5 | -3.4 | -4.4 |
Institutional ownership, Q1 2024
32.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.45 mm |
Total shares | 3.56 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Gk Partners ApS | 3.56 mm | $4.45 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 May 24 | Gk Partners ApS | Common Stock | Buy | Acquire P | No | No | 1 | 30,000 | 30.00 k | 22,382,106 |
14 May 24 | Gk Partners ApS | Common Stock | Other | Acquire J | No | No | 1 | 20,106,062 | 20.11 mm | 22,352,106 |
29 Apr 24 | Gk Partners ApS | Common Stock | Buy | Acquire P | No | No | 1 | 30,000 | 30.00 k | 2,246,044 |
20 Mar 24 | Rouf Henrik | Common Stock | Sell | Dispose S | No | No | 1 | 250,000 | 250.00 k | 585,018 |
20 Mar 24 | Gk Partners ApS | Common Stock | Buy | Acquire P | No | No | 1 | 250,000 | 250.00 k | 2,216,044 |
14 Mar 24 | Gk Partners ApS | Common Stock | Buy | Acquire P | No | No | 1 | 25,000 | 25.00 k | 1,966,044 |
31 Jan 24 | Gk Partners ApS | Common Stock | Buy | Acquire P | No | No | 1 | 46,000 | 46.00 k | 1,941,044 |
15 Jan 24 | Gk Partners ApS | Common Stock | Sell | Dispose S | No | No | 0.97 | 1,701,527 | 1.65 mm | 1,895,044 |
11 Jan 24 | Gk Partners ApS | Common Stock | Buy | Acquire P | No | No | 1 | 55,000 | 55.00 k | 3,596,571 |
19 Dec 23 | Gk Partners ApS | Common Stock | Buy | Acquire P | No | No | 1 | 25,000 | 25.00 k | 3,541,571 |
Press releases
Orocidin – New Insights Into The Treatment Of Periodontitis
11 Jun 24
Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of Directors
4 Jun 24
Nordicus Partners Corporation Engages FORCE Family Office
23 May 24
Nordicus Partners Corporation Acquires 95% Stake in Orocidin A/S
15 May 24
Nordicus Partners Corporation Uplists to OTCQB
9 May 24